Brivaracetam: a novel antiepileptic drug for focal-onset seizures.

Ther Adv Neurol Disord · 2018 · PMC5784556 · PMID 29399049

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

35 – 37 This primary efficacy endpoint did not reach statistical significance in the flexible dose study in patients receiving BRV 50–150 mg/day, 38 nor for lower doses of 5 mg and 20 mg/day. 35 , 37 , 39 Statistically significant seizure freedom rates of 4.0–5.2% were achieved in patients treated with 100–200 mg BRV daily in the largest study. 40 Health-related quality of l

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.